This ICR is approved on the understanding that results of these surveys will be primarily for internal agency use only. The following terms of clearance also apply. (1) To the extent that results will be made public, all study limitations will need to be clearly discussed in supporting statements and in public reports. Since NIH does not plan for robust follow-up to minimize non-response, NIH should report the response rates and analyze for potential non-response bias. (2) This generic ICR is approved for the purpose of conducting customer satisfaction surveys of similar scope to the prototype ICs submitted as part of this package. (3) Given that this generic ICR is not intended to be a robust evaluation of program quality but, rather, informal customer satisfaction surveys, NIH shall consider whether it really needs to survey over 58,000 respondents. Prior to submission of individual generic ICs under this umbrella ICR, NIH will conduct a power analysis for each generic IC and describe in the supporting statement how the target sample sizes were determined and why they need to be so large for purposes of a customer satisfaction survey. (4) When providing assurances of confidentiality, NIH will disclose on all materials sent to respondents the statutory authority NIH has to provide assurances of confidentiality. If NIH determines it does not have this statutory authority and has not obtained an equivalent authority (e.g. certificate of confidentiality), NIH will not provide assurances of confidentiality. (5) NIH will adhere to OMB standards regarding race/ethnicity questions on all IC instruments. (6) This generic ICR is approved consistent with NIH agreement to submit individual collections to OMB as they are implemented, along with all necessary supporting statements (to include information about research design and analysis, incentives, burden estimates, approaches to address non-response bias, etc). OMB will aim to review each IC submission within 14 days; however, OMB approval should not be assumed if not explicitly granted, even if 14 days have elapsed since submission.
Inventory as of this Action
Requested
Previously Approved
11/30/2010
36 Months From Approved
58,335
0
0
21,884
0
0
0
0
0
The Warren Grant Magnuson Clinical Center will conduct surveys of its customers and other partners to assess perceptions about the quality of care and services provided at the Clinical Center. Data will be used to drive performance improvement.
This is an ongoing performance improvement program, designed to gather the perceptions of the quality of care and services provided to the Clinical Center customers and other partners; these surveys should continue to drive service and program changes, as they have in the past. Such voluntary customer survey work is required by EO 12862.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Form 1 Survey of Acute Graft Versus Host Disease (GVHD) Practice Patterns
Part B.doc
Survey of Acute Graft Versus Host Disease (GVHD) Practice Patterns